InterCure Ltd. (INCR)vsZoetis Inc (ZTS)
INCR
InterCure Ltd.
$4.47
0.00%
HEALTHCARE · Cap: $66.62M
ZTS
Zoetis Inc
$77.80
-0.55%
HEALTHCARE · Cap: $32.80B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 3818% more annual revenue ($9.53B vs $243.12M). ZTS leads profitability with a 27.7% profit margin vs -13.2%. ZTS earns a higher WallStSmart Score of 58/100 (C).
INCR
Hold38
out of 100
Grade: F
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INCR.
Margin of Safety
+10.3%
Fair Value
$143.36
Current Price
$77.80
$65.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 23.9% year-over-year
Every $100 of equity generates 83 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
Smaller company, higher risk/reward
Operating margin of 0.0%
ROE of -9.0% — below average capital efficiency
Earnings declined 84.7%
Trading at 10.2x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : INCR
The strongest argument for INCR centers on Price/Book, Revenue Growth. Revenue growth of 23.9% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : INCR
The primary concerns for INCR are Market Cap, Operating Margin, Return on Equity.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.
Key Dynamics to Monitor
INCR profiles as a growth stock while ZTS is a declining play — different risk/reward profiles.
ZTS carries more volatility with a beta of 0.74 — expect wider price swings.
INCR is growing revenue faster at 23.9% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (58/100 vs 38/100), backed by strong 27.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
InterCure Ltd.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Syneos Health, Inc., a contract research organization, provides various clinical development services for the medical device and biopharmaceutical industries in North America, Europe, the Middle East and Africa, Asia-Pacific, and Latin America. The company is headquartered in Raleigh, North Carolina.
Visit Website →Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?